Tata Chemicals to acquire Novabay Pte. for EUR 25 Million
Tata Chemicals International Pte. Limited will acquire 100% of Novabay Pte. Limited for EUR 25 Million. Novabay, a Singapore-based firm, manufactures premium grade sodium bicarbonate for pharma, food, and personal care. The acquisition aims to strengthen Tata Chemicals' presence in high-value product segments and is expected to complete by March 2026.
The acquisition is significant as it expands Tata Chemicals' product portfolio into premium-grade sodium bicarbonate, catering to high-growth sectors like pharmaceuticals and personal care. While it is a strategic move, the immediate financial impact needs to be assessed against the enterprise value and potential synergies.
The acquisition of Novabay Pte. Limited by Tata Chemicals is a strategic move to strengthen its position in the premium-grade sodium bicarbonate market, which is expected to drive long-term growth and value creation. This aligns with the company's strategy to expand in high-value, non-cyclical product segments.
Tata Chemicals International Pte. Limited (TCIPL), a wholly owned subsidiary of Tata Chemicals Limited, has executed a Share Purchase Agreement (SPA) to acquire 100% equity share capital of Novabay Pte. Limited (Novabay). The acquisition is contingent upon the fulfillment of various conditions precedent as specified in the SPA and is expected to be completed by March 2026.
Novabay is a Singapore-based company engaged in the manufacture and sale of premium grade sodium bicarbonate, serving Pharma, Food, Personal Care in Europe, Americas, Oceania, ASIA, Middle East, and ASEAN markets. Its issued and paid-up share capital is US$ 35,532,140. For Calendar Year 2024, Novabay's turnover was SGD 29.49 Million (approximately ₹182 crore). The company was incorporated in November 2015 and is a wholly owned subsidiary of Novacarb, based in France. Novabay's turnover for CY2023 was SGD 25.93 Million and for CY2022 was SGD 27.68 Million.
The acquisition is in line with Tata Chemicals' strategic intent to strengthen its capabilities in premium-grade products. Novabay is among the largest premium sodium bicarbonate producers in the Asia-Pacific region (excluding China), holding key cGMP, API, and related certifications, supported by a fully automated facility. With a current capacity of approximately 60,000 tons and potential to expand to 100,000 tons, Novabay is well-positioned for growth.
The cash consideration for the acquisition is at an enterprise value of EUR 25 Million (equivalent to approximately SGD 37.8 Million), subject to net debt, net working capital, and other customary adjustments. The proposed acquisition does not fall within related party transactions, and the promoter/promoter group/group companies of Tata Chemicals have no interest in Novabay. No governmental or regulatory approvals are required for the proposed acquisition.
What to do with a filing like this
Tata Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tata Chemicals Limited. Read the original for the full detail.